Back to results
US 2023/0201323 A1Published application
Vaccine formulations
AssigneeEqualy S.A.
InventorJean-Marie SAINT-REMY
Life of this patent
Estimating the term…
Abstract
A method to elicit CD4+ T cells with an immune suppressive function towards a given MHC Class II epitope present in a specific target tissue and/or to elicit CD4+ T cells harbouring homeostasis restoration properties for a specific target tissue, based on an MHC Class II epitope modified by the addition of a redox motif, the corresponding modified epitopes, pharmaceutical uses, kits of parts, and gene edition system for use in a patient.
Claims8
-9. (canceled)
A peptide fragment of a non-human nuclease comprising:
- a MHC Class II epitope, and
- a CXXC motif adjacent to the fragment of the nuclease or separated from the fragment of the specific nuclease by a linker of up to 7 amino acids, wherein C stands for cysteine or selenocysteine and X stands for any amino acid,
- wherein the peptide fragment is suitable for use in combination with a gene edition system comprising said nuclease, preferably in the treatment of a genetic disease.
-15. (canceled)
A kit of parts comprising:
- a gene edition system with a specific nuclease or a nucleic acid molecule encoding the specific nuclease, and
- a peptide fragment of the specific nuclease being a MHC Class II epitope, the peptide fragment further including a CXXC motif adjacent to the fragment of the specific nuclease or separated from the fragment of the specific nuclease by a linker of up to 7 amino acids, wherein C stands for cysteine or selenocysteine and X stands for any amino acid.
Dependencies are inferred from the claim text.